Literature DB >> 20472995

Efficacy of continuous hemodiafiltration with a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome.

Kenichi Matsuda, Takeshi Moriguchi, Shigeto Oda, Hiroyuki Hirasawa.   

Abstract

BACKGROUND/AIMS: In the pathophysiology of acute respiratory distress syndrome (ARDS), the increase in capillary and alveolar permeability caused by various humoral mediators and resultant pulmonary interstitial edema play major roles. In this study, the efficacy of continuous hemodiafiltration using a cytokine-adsorbing hemofilter with a membrane made of polymethylmethacrylate (PMMA-CHDF) in the treatment of ARDS patients was investigated.
MATERIALS AND METHODS: Fifty-one patients with a diagnosis of ARDS complicated by renal failure and without prior steroid therapy were enrolled in this study. Changes in respiratory index (RI), positive end-expiratory pressure, central venous pressure (CVP) and blood levels of TNFalpha, IL-6 and IL-8 before/after blood purification for 3 days as well as the cumulative water balance during the 3-day treatment and 28-day cumulative survival rate were compared between 2 patient groups. One group underwent PMMA-CHDF and the other intermittent hemodialysis (IHD) without water removal for elimination of metabolites and continuous hemofiltration (CHF) for fluid management.
RESULTS: Blood purification for 3 days significantly decreased blood levels of cytokines and successfully removed water without changing CVP in the PMMA-CHDF group, but not in the IHD+CHF group. Significant correlations between changes in blood levels of cytokines (IL-6 and IL-8) and changes in RI were demonstrated in the PMMA-CHDF group. The 28-day cumulative survival rate in the PMMA-CHDF group (68.8%) was significantly higher than that in the IHD+CHF group (36.8%).
CONCLUSIONS: Cytokine removal therapy with PMMA-CHDF is expected to be useful as a new therapeutic modality in ARDS patients for non-renal indications. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472995     DOI: 10.1159/000314856

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  6 in total

Review 1.  Changes in acute blood purification therapy in critical care: republication of the article published in the Japanese Journal of Artificial Organs.

Authors:  Taka-Aki Nakada; Shigeto Oda; Ryuzo Abe; Noriyuki Hattori
Journal:  J Artif Organs       Date:  2019-06-24       Impact factor: 1.731

2.  Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013.

Authors:  Toshiaki Arimura; Masanori Abe; Hidetoshi Shiga; Hiroshi Katayama; Kazo Kaizu; Shigeto Oda
Journal:  J Artif Organs       Date:  2017-06-09       Impact factor: 1.731

Review 3.  Beyond Low Tidal Volume Ventilation: Treatment Adjuncts for Severe Respiratory Failure in Acute Respiratory Distress Syndrome.

Authors:  Vikram Fielding-Singh; Michael A Matthay; Carolyn S Calfee
Journal:  Crit Care Med       Date:  2018-11       Impact factor: 7.598

4.  Continuous blood purification treatment for endotoxin-induced acute respiratory distress syndrome.

Authors:  Y Jiang; R Lin; Y Xu; S Zhang; K Cui; M Zhu; A Li; C Chen; J Yang; W Yang
Journal:  Braz J Med Biol Res       Date:  2017-02-16       Impact factor: 2.590

5.  Continuous Renal Replacement Therapy in Pediatric Severe Sepsis: A Propensity Score-Matched Prospective Multicenter Cohort Study in the PICU.

Authors:  Huijie Miao; Jingyi Shi; Chunxia Wang; Guoping Lu; Xiaodong Zhu; Ying Wang; Yun Cui; Yucai Zhang
Journal:  Crit Care Med       Date:  2019-10       Impact factor: 7.598

6.  Clinical efficacy of blood purification using a polymethylmethacrylate hemofilter for the treatment of severe acute pancreatitis.

Authors:  Kiyohiko Kinjoh; Ryoji Nagamura; Yutaka Sakuda; Shoki Yamauchi; Hideta Takushi; Tadashi Iraha; Koji Idomari
Journal:  Acute Crit Care       Date:  2022-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.